New Two-Pronged immune cell therapy tested for tough lymphomas

NCT ID NCT05098613

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 12, 2026 · Updated 10 times

Summary

This early-stage trial is testing the safety and finding the right dose of a new type of CAR T-cell therapy for people with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own modified immune cells designed to attack cancer by targeting two proteins (CD19 and CD22) on the lymphoma cells. The study will enroll up to 68 adolescents and adults to see how well they tolerate the treatment and if it shows signs of fighting the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B-CELL NON-HODGKIN LYMPHOMA (B-NHL) CNS LYMPHOMA MANTLE CELL LYMPHOMA (MCL) NON-HODGKIN LYMPHOMA